Calcium Channel Blockers

ApprovedSmall molecule

SSeoul National University Hospital

Calcium Channel Blockers is one of 110 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Systemic SclerosisActive, not recruiting

COVID-19Active, not recruiting

Sleep ApneaActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

Systemic SclerosisPreclinical

Active, not recruiting

COVID-19Approved

Active, not recruiting

Sleep ApneaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Calcium Channel Blockers

SSeoul National University Hospital

Approved

1 2

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 3

SARS-COV-2 VACCINE

Moderna

Preclinical

2 4

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—5

Piperacillin/tazobactam

Pfizer

Preclinical

1 6

Orap

Teva

Preclinical

1 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Aprotinin

Bayer

Preclinical

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

MRNA COVID-19 Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Not yet recruiting

Pneumonia

NCT07262710

Clinical

Trials by Indication[1]

Systemic Sclerosis1 trial

Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study

Terminated·SSeoul National University Hospital··NCT02642146·71 enrolled

Sleep Apnea1 trial

Effect of Antihypertensive Agents Over Sleep Apnea

Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT01896661·53 enrolled

Injury1 trial

Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury?

Completed·MMansoura University·Phase 4·NCT01675362·160 enrolled

Pneumonia1 trial

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

Not yet recruiting·—··NCT07262710·13,656 enrolled

Preterm Labor1 trial

Tocolysis in Prevention of Preterm Labor

Unknown status·—·Phase 4·NCT03298191·300 enrolled

3 more indications

COVID-191 trial

Coronavirus (COVID-19) ACEi/ARB Investigation

Suspended·NNational University of Ireland, Galway, Ireland·Phase 4·NCT04330300·2,414 enrolled

Hypertensive1 trial

Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Completed·JJuntendo University·Phase 4·NCT00294567·199 enrolled

Randomized1 trial

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

Completed·OOSCAR Study·Phase 4·NCT00134160·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Calcium Channel Blockers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcium Channel Blockers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcium Channel Blockers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSeoul National University Hospital

Calcium Channel Blockers

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Systemic Sclerosis1 trial

Sleep Apnea1 trial

Injury1 trial

Pneumonia1 trial

Preterm Labor1 trial

COVID-191 trial

Hypertensive1 trial

Randomized1 trial

References

Drug Info

Quick Facts

Related News